Background {#Sec1}
==========

Malaria, caused by infection with parasites of the genus *Plasmodium*, remains a significant public health concern \[[@CR1]\]. Despite a vaccine in pilot implementation trials \[[@CR2]\] and widespread application of control measures \[[@CR3]\], the disease is still responsible for a huge burden of mortality and morbidity worldwide and a concerning increase in incidence has been seen in previously well-controlled areas \[[@CR3]\].

With repeated exposure to infection, individuals in malaria-endemic regions develop naturally acquired immunity (NAI), first to the most severe clinical forms, such as cerebral malaria and then more slowly to infection itself \[[@CR1]\]. Although the role of antibodies in controlling parasite density, symptomatology and severity of disease is well established \[[@CR4], [@CR5]\], less is known about mechanism in terms of the role of the innate and cellular immune responses \[[@CR6]\]. Increased understanding of the immune response to malaria, in particular those that mediate NAI, could aid identification of diagnostic and prognostic markers, inform vaccine development and assist with the identification of treatment strategies to modify the immunological mechanisms mediating severe pathology \[[@CR1]\].

Transcriptomics, which allows the expression of thousands of genes to be assessed in parallel for a single RNA sample, is an exciting, expanding area of research with vast potential application in the field of infection \[[@CR7]\]. Facilitating a systems biology approach, gene expression data from high-throughput technologies (such as microarrays \[[@CR8]\] and next generation sequencing enabling RNA sequencing for bulk cell populations and at single-cell resolution \[[@CR9], [@CR10]\]) can allow greater understanding of individuals' response to infection. To date, expression data have been used to dissect mechanisms of vaccine immunogenicity \[[@CR11]\], inform the design of new vaccines \[[@CR12], [@CR13]\], predict response to infection and outcome \[[@CR14], [@CR15]\], characterize and improve understanding of sepsis \[[@CR16]\], and offer a novel approach to the diagnosis of infectious pathogens \[[@CR17]--[@CR19]\] together with RNA expression in the pathogen \[[@CR20]\].

Given the limited understanding of the mechanisms of NAI to malaria from traditional immunological studies, a systems approach characterizing the gene expression patterns associated with infection could provide novel and valuable insights \[[@CR21], [@CR22]\]. Transcriptional profiling of the immune response to malaria in humans to date has sought to identify markers to aid diagnosis \[[@CR23]\], to understand the pathogenicity of severe disease \[[@CR24]\] and dissect the mechanisms of NAI \[[@CR25], [@CR26]\]. However, interpreting this body of work is difficult given considerable variation in study design, definition of disease, patient selection and methodology employed.

This review outlines a comprehensive analysis of all GEP studies of the human immune response to malaria with two aims: (i) to understand the application of this technology to date, in particular how these studies have informed understanding of NAI; and (ii) to determine the extent of variability in methodology between studies to allow informed comparison of data and interpretation of results.

Methods {#Sec2}
=======

A search of Gene Expression Omnibus (GEO) \[[@CR27]\] for datasets including the search terms; 'plasmodium' or 'malaria' or 'sporozoite' or 'merozoite' or 'gametocyte' and 'Homo sapiens' was performed on 10th September 2019. Each of these datasets were examined and those not relating to the human immune response to malaria infection or using the *Homo sapiens* platform excluded. Of note, datasets of gene expression changes in relation to malaria vaccines were excluded.

Results {#Sec3}
=======

Studies identified {#Sec4}
------------------

The search identified 30 GEO datasets. Seven of these datasets were excluded, as published analyses were unavailable. Twenty-three datasets and 25 related publications were therefore included in the final review (Table [1](#Tab1){ref-type="table"} and Additional file [1](#MOESM1){ref-type="media"}: Figure S1). All datasets related to *Plasmodium falciparum* infection except two that related to *Plasmodium vivax* infection (Table [1](#Tab1){ref-type="table"}). The majority of datasets included samples from individuals infected with malaria 'naturally' in the field (n = 13, 57%), however some related to controlled human malaria infection (CHMI) studies (n = 6, 26%), or cells stimulated with *Plasmodium* in vitro (n = 6, 26%). Studies included samples from individuals with a wide range of ages (from 2 months---varying ages of adulthood) with differing degrees of prior exposure and, therefore, NAI to malaria. Samples were often collected as part of wider immuno-epidemiological studies or vaccine trials, leading to variation in study design and sampling intervals.Table 1Summary of gene expression datasets investigating the human immunological response to malaria infectionGEO seriesTitle of datasetPublicationDesignInfection/antigenic StimulationSpeciesTissueAgeParticipant originExpression profilingSubjects (samples)^a^ControlsPlatform namePlatform technologyGSE2900Host response malariaGriffiths et al. (2005)Comparison of GEP in febrile children with convalescent samples 2 weeks post dischargeField*P. falciparum*Whole blood: PAX geneChildren 2--126 monthsKenyaArray22 (28)Subject paired samples: diagnosis and post treatmentLC-36Spotted DNA/cDNAGSE5418Gene expression analysis in malaria infectionOckenhouse et al. (2006)Comparison of GEP in early, pre-symptomatic blood-stage infection post CHMI with symptomatic malaria-experienced adults with naturally acquired malariaCHMI and Field*P. falciparum*PBMCAdults; 19--49 yearsUSA and CameroonArray37 (74)22 un-infected malaria-naïve American adultsAffymetrix human genome U133A arrayIn situ oligonucleotideGSE15221Malaria primes the innate immune response due to IFNγ induced enhancement of Toll-like receptor expression and functionFranklin et al. (2009) and Sharma et al. (2011) and Hirako et al. (2018)Comparison GEP at malaria diagnosis and 28 days post treatmentField*P. falciparum*PBMCAdults 30 ± 10 yearsBrazil; Porto VelhoArray21 (42)Subject paired samples: diagnosis and post treatmentIllumina human-6 v2.0Oligonucleotide beadsGSE26876Time kinetics of gene expression in NK92 cells after *P. falciparum*-iRBC encounterDe Carvalho et al. (2011)Comparison of GEP variation of NK92 cells after 6, 12, and 24 h of co-culture with either infected or uninfected RBC compared to time-point 0In vitro---iRBC*P. falciparum*NK92 cell lineN/AN/AArrayN/A (12)Paired samples: pre and post exposureAffymetrix human gene 1.0 ST arrayIn situ oligonucleotideGSE33811Paired whole blood human transcription profiles from children with severe malaria and mild malariaKrupka et al. (2012)Comparison of GEP in severe malaria and subsequent mild malaria in same subjects 1 month laterField*P. falciparum*Whole blood: tri-reagent BDChildren: 8--45 monthsMalawiArray5 (10)Subject paired samples: severe and mild malariaAffymetrix Human Gene 1.0 ST ArrayIn situ oligonucleotideGSE34404The genomic architecture of host whole blood transcriptional response to malaria infectionIdaghdour et al. (2012)Comparison of GEP in mild malaria with age matched un-infected controlsField*P. falciparum*Whole blood: TempusChildren; median age 3.7 yearsBeninArray94 subjects (94) and 64 controls (64)Uninfected age matchedIllumina HumanHT-12 V4.0 expression bead chipOligonucleotide beadsGSE55843Loss and dysfunction of Vdelta2 + gamma delta-low T cells is associated with clinical tolerance to malariaJagannathan et al. (2014)Comparison of GEP of Vδ2 + T cells from children with 'high' and 'low' episodes of malaria in the preceding yearIn vitro---iRBC*P. falciparum*Vδ2 + T cellsChildren: 4--5 yearsUgandaArray78 (156)N/AAgilent-039494 SurePrint G3 Human GE v2 8 × 60K Microarray 03938In situ oligonucleotideGSE53292Transcriptomic analysis of Plasmodium PBANKA, PBSLTRiP-KO, PB268-KO parasite infected and uninfected host cellJaijyan et al. (2015)Comparison of GEP of uninfected HepG2 with those infected with wild-type and knock out sporozoitesIn vitro---sporozoites*P. falciparum*HepG2 cellsN/AN/AHigh throughput sequencingNKNKIllumina Genome Analyzer IIx (Homo sapiens)High-throughput sequencingGSE50957Molecular hallmarks of experimentally acquired immunity to malaria \[Pilot Study\]Tran et al. (2016) and Vallejo et al. (2018)Comparison of GEP pre and post infectionCHMI*P. falciparum*Whole blood: PAX geneAdults: 19--22 yearsUSAHigh throughput sequencing5 (10)Subject paired samples: Pre and post infectionIllumina HiSeq 2000 (Homo sapiens)High-throughput sequencingGSE52166Molecular hallmarks of naturally acquired immunity to malariaTran et al. (2016)Comparison of GEP pre and post infectionField*P. falciparum*Whole blood: TempusAdults and Children 13.5--23.3 yearsMalawiHigh throughput sequencing8 (16)Paired same subject pre infectionIllumina HiSeq 2000 (Homo sapiens)High-throughput sequencingGSE64338Expression data from whole blood samples of Rwandan adults with mild malaria with matched sample 30 days later (convalescence)Subramaniam et al. (2015)Comparison of GEP in mild malaria and 30 days laterField*P. falciparum*Whole blood: Tri-Reagent BDAdultsRwandanArray19 (38)Subject paired samples: diagnosis and post treatment\[HuGene-1_0-st\] Affymetrix Human Gene 1.0 ST ArrayIn situ oligonucleotideGSE64493FCRL5 delineates functionally impaired memory B cells associated with malaria exposureSullivan (2015)Comparison of GEP between classical and atypical memory B cells in Uganda childrenField*P. falciparum*PBMCChildren 8--10 yearsUgandaArray12NKAgilent-039494 SurePrint G3 Human GE v2 8 × 60K Microarray 039381In situ oligonucleotideGSE67184Transcription profiling of malaria-naïve and semi-immune colombian volunteers in a *Plasmodium vivax* sporozoite challengeRojas-Penas (2015), Vallejo (2018) and Gardinassi (2018)Comparison of GEP changes between malaria naïve and semi-immune adults pre-infection and at diagnosisCHMI*P. vivax*Whole blood: TempusAdultsColumbiaHigh throughput sequencing12 (24)Subject paired samples: pre-infection and diagnosisIllumina HiSeq 2500 (Homo sapiens)High-throughput sequencingGSE67469Transcription profiling of malaria-naïve and semi-immune colombian volunteers in a *Plasmodium vivax* sporozoite challengeRojas-Penas (2015)Comparison of GEP changes between malaria naïve and semi-immune adults over the time-course of malaria infection: pre-infection, day 5, day 7, day 9, diagnosis and month 4CHMI*P. vivax*Whole blood: TempusAdultsColumbiaRT-qPCR16 (85)Subject paired samples: Pre infection and multiple time-points post infectionFluidigm 96Ã---96 nanofluidic arrays for 96 genes: blood informative transcriptsRT-PCRGSE7586Genome wide analysis of placental malariaMuehlenbachs (2007)Comparison of GEP in women with placental malaria and those withoutField*P. falciparum*PlacentaAdultsTanzaniaArray20 (20)NK\[HG-U133_Plus_2\] Affymetrix Human Genome U133 Plus 2.0 ArrayIn situ oligonucleotideGSE77122Involvement of β-defensin 130 (DEFB130) in the macrophage microbicidal mechanisms for killing *Plasmodium falciparum*Terkawi (2017)Human monocyte-derived macrophages were co-cultured with *P. falciparum* iRBCs, saponin-treated iRBCs, or non-infected RBCsIn vitro---iRBC*P. falciparum*MacrophagesNKNKArrayNK (8)NKAgilent-028004 SurePrint G3 Human GE 8 × 60K MicroarrayIn situ oligonucleotideGSE93664Comparison of the transcriptomic profile of *P. falciparum* reactive polyfunctional and IFNγ monofunctional human CD4 T cellsBurel (2017)Comparison of GEP in monofunctional and polyfunctional IFN producing T cells collected 21 days post CHMI infectionCHMI + in vitro---iRBC*P. falciparum*IFN producing T cells18--42 yearsAustraliaArray8 (2)NK\[HuGene-2_0-st\] Affymetrix Human Gene 2.0 ST ArrayIn situ oligonucleotideGSE100562RNA-sequencing analysis of response to *P. falciparum* infection in Fulani and Mossi ethnic groups, Burkina FasoQuin (2017)Comparison of GEP in onocytes and CD14− cells in *P. falciparum* infected and uninfected malaria-exposed Fulani and Mossi sympatric ethnic groupsField*P. falciparum*Monocytes (CD14+) and lymphocytes (CD14−)15--24 yearsBurkino FasoHigh throughput sequencing23 (23)NKIllumina HiSeq 2500 (Homo sapiens)High-throughput sequencingGSE1124Whole blood transcriptome of childhood malariaBoldt (2019)Comparison of GEP of children with asymptomatic parasitemia, uncomplicated malaria, malaria with severe anaemia and cerebral malariaField*P. falciparum*Whole blood: PAX gene0.5--6 yearsGabonArrayNKHealthy control children\[HG-U133A\] Affymetrix Human Genome U133A ArrayIn situ oligonucleotideGSE114076Differential gene expression profile of human neutrophils cultured with *Plasmodium falciparum*-parasitized erythrocytesTerkawi (2018)Comparison of GEP in neutrophils incubated with iRBC or non-infected RBCIn vitro---iRBC*P. falciparum*NeutrophilsNKNKArray1 (8)Culture with non-infected RBCAgilent-072363 SurePrint G3 Human GE v3 8 × 60K MicroarrayIn situ oligonucleotideGSE97158Transcriptional responses induced by controlled human malaria infection (CHMI)Rothan (2018)Comparison of GEP in whole blood pre and post sporozoite CHMI in malaria exposed adultsCHMI*P. falciparum*Whole blood: PAX geneAdultsTanzaniaHigh throughput sequencing10 (40)Subject paired samples: pre and post CHMIIllumina HiSeq 2000 (Homo sapiens)High-throughput sequencingGSE65928Malaria-associated atypical memory B cells exhibit markedly reduced B cell receptor signaling and effector functionPortugal (2015)Comaprison of GEP of naïve B cells, classical and atypical memory B cells in immune adultsField*P. falciparum*B cellsAdults: 18--37 yearsMaliArray20 (20)US healthy adults\[HuGene-2_0-st\] Affymetrix Human Gene 2.0 ST Array \[transcript (gene) version\]In situ oligonucleotideGSE72058Activated neutrophils are associated with pediatric cerebral malaria vasculopathy in Malawian childrenFeintuch (2016)Comparison of GEP in cerebral malaria between children with malaria retinopathy and those withoutField*P. falciparum*Whole blood: Tri-Reagent BDChildren 6 month--12 yearsMaliArray98 (98)NK\[HuGene-1_0-st\] Affymetrix Human Gene 1.0 ST Array \[transcript (gene) version\]In situ oligonucleotide*PBMC* peripheral blood mononuclear cells, *GEP* gene expression profile, *CHMI* controlled human malaria infection, *iRBCs* infected red blood cells, *N/A* not applicable, *NK* not known^a^Samples analysed for publication

Review of methodological approaches {#Sec5}
-----------------------------------

Significant heterogeneity in the datasets was found in terms of study design, sample type, platform used and method of analysis (Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"} and Fig. [1](#Fig1){ref-type="fig"}), making direct comparison of results between studies difficult. Most datasets were generated from whole blood samples (n = 11, 48%), however some used PBMCs (n = 3, 13%) or individual tissue or cells types (n = 8, 35%) (Table [1](#Tab1){ref-type="table"}). For the majority of studies, expression profiling was performed by array (n = 16, 70%), with others using high throughput sequencing (n = 6, 26%) or RT-qPCR \[[@CR28]\] (n = 1, 4%) (Table [1](#Tab1){ref-type="table"}). There was heterogeneity in data generation between studies with variation in methods used for normalization of data and adjustment for co-variables (Table [2](#Tab2){ref-type="table"}). Thresholds for significance varied considerably and not all studies applied corrections for multiple testing. Choice of database used for gene ontology analysis also varied and there was variable, often incomplete reporting of analysis methods used (Table [2](#Tab2){ref-type="table"}).Table 2Comparison of methodological approaches for analysis of gene expression dataDatasetData generationGene ontology analysisGEO seriesPublicationRNA Quantification PlatformNormalizationAdjustment for covariatesDefinition expressionExpressed genesThreshold FCThreshold PTestMultiple testingGO analysisThreshold GO enrichment pTestMultiple testingGSE2900Griffiths (2005)Stanford University cDNA lymphochip two color microarrayScaled to geometric mean of sample:reference signal ratio from all array featuresNSSignal threshold98692.5 (from median in \> 4 samples)0.1PermutationFDRNANANANAGSE5418Ockenhouse (2006)Affymetrix U133A GeneChipsRMANSNSNSNo0.01SAM, t-testFDROnto Express and Pathway Architect*0.05*NSFDRGSE15221Franklin (2009) and Sharma (2011)Illumina Human WG-6 v2.0Cubic splineNSSignal thresholdNS1.70.01Paired t-testFDROnto ExpressVaryingNSNSGSE15221Hirako (2018)Illumina Human WG-6 v2.0Cubic splineNSSignal thresholdNS1.50.01Permutation and t-testFDRDAVID, GSEA0.05MultipleFDRGSE26876de Carvalho (2011)Affymetrix Human Gene 1.0 ST ArrayRMANSNSNS1.50.05Student t-testNoIngenuity pathway analysisNSNSNSGSE33811Krupka (2012)Affymetrix Human Gene 1.0 ST ArrayRMA and QuantileNSSignal and variation threshold311020.05Paired t-testNoGene set enrichment analysis on selected GO terms*0.01*Paired t-testFDRGSE34404Idaghdour (2012)Illumina Human HT-12 BeadChipsQuantileLocation, Sex, Hb, total cell counts (RBCs and WBCs) and ancestrySignal and normality thresholdNS2 (for comparison)0.01ANOVA, ANCOVAFDRGene set enrichment analysis on customized MsigDB database*0.05*NSBonferroniGSE55843Jagannathan (2014)Agilent Sure Print G3 Human Gene Expression 8 × 60K v2 gene expression microarraysQuantileNSSignal thresholdNS20.05SAMFDRNANANANAGSE53292Jaijyan (2015)Illumina Genome Analyzer Iix 72SENSNSNSNSNS0.05t-testNoGeneCodis3, Bingo 2.3 plugin (Cytoscape 2.8.3)*0.05*NSNSGSE50957 GSE52166Tran (2016)Illumina HiSeq 2000 2 × 100 PETAMMBatch, Sex, Age, Pre-infection baselineSignal and variation threshold, removal Y chromosomesNS1.50.05LimmaFDRIngenuity pathway analysis*0.05*Fisher exact testFDRGSE50957 GSE67184Vallejo (2018)Illumina HiSeq 2000 2 × 100 PECPM, TPMNSSignal thresholdNSNS0.05EdgeRFDRWGSEA, ToppGene, STRING*0.05*MultipleFDRGSE64338Subramaniam (2015)Affymetrix Human Gene 1.0 ST ArrayNonlinear normalization based on Li-Wong methodsNSNSNS1.20.001Paired t-testFDRIngenuity Pathway Analysis*0.05*NSFDRGSE64493Sullivan (2015)Agilent Sure Print G3 Human Gene Expression 8 × 60K v2 gene expression microarraysQuantileNSSignal thresholdNS1.50.03LimmaFDRDAVID*0.05*NSFDRGSE67184Rojas-Penas (2015)Illumina HiSeq 2500 2 × 100 PESNMLocation/time-point, subject (random effect)Signal threshold6154No0.05NSFDRNANANANAGSE67184Gardinassi (2018)Illumina HiSeq 2500 2 × 100 PENSNSNSNSNo0.05Limma, repeated measures ANOVAFDRGSEA on blood transcriptome modules (BTM, Li et al.)*0.05*permutationFDRGSE7586Muehlenbachs (2007)Affymetrix U133 Plus 2.0 GeneChipGC RMANSNSNS2.50.01t-testNoNANANANAGSE77122Tarawa (2017)Agilent Sure Print G3 Human Gene Expression 8 × 60K gene expression microarraysEach gene expression array dataset was normalized to the in silicon pool for the macrophages cultured with RBCsNSNSNSNo0.05Paired t-testNoDAVID*0.05*Fisher exact testNoGSE93664Burl (2017)Affymetrix Human Gene ST 2.0 gene arrayRMANSNSNS20.05NSNoSTRING*0.01*NSCorrected unspecifiedGSE100562Quin (2017)Illumina HiSeq 2500 2 × 50 PENSNSNSNSNo0.05LimmaFDRNANANANAGSE1124Boldt (2019)Affymetrix U133A + B GeneChipsRMANSSignal thresholdNS1.90.004SAMFDRDAVID and Ingenuity Pathway Analysis*0.05*NSNSGSE114076Terkawi (2018)Agilent Sure Print G3 Human Gene Expression 8 × 60K gene expression microarraysEach gene expression array dataset was normalized to the in silicon pool for the neutrophils cultured with RBCsNSNSNS20.01LimmaNoGenomatix GeneRanker, DAVID, NET-GE and Enricher*0.05*NSCorrected unspecifiedGSE97158Rothan (2018)Illumina HiSeq 2500 2 × 51 PETMMBlocking by subject, in two separate models interaction with cell count and time of parasitemia was addedSignal threshold16,4731.50.05LimmaFDRGSEA (camera) on blood transcriptome modules (BTM, Li et al.)*0.05*Fisher exact testFDRGSE65928Portugal (2015)Affymetrix Human Gene ST 2.0 gene arrayRMANSNSNSNS0.05ANOVAFDRIngenuity pathway analysisNSNSNSGSE72058Feintuch (2016)Affymetrix Human Gene 1.0 ST arrayRMA and QuantilePeripheral parasitemiaNSNSNo0.05t-testNoGSEA, CateGOrizer and ingenuity pathway analysis0.2 and 0.06NSFDR*FDR* false discovery rate, *Hb* haemoglobin, *NA* not available, *NS* not specified in publication, *RBCs* red blood cells, *RMA* Robust Multichip average, *SNM* supervised normalization of microarray, *TMM* trimmed mean of M-values, *GEO* Gene Expression Omnibus, *GE* gene ontology Fig. 1Comparison of key methodological variables between datasets or publications. **a** Antigenic stimulation; *CHMI* controlled human malaria infection, *'field'* infection naturally by mosquito bite, *'in-vitro'* in vitro stimulation by sporozoites or infected red blood cells. Some datasets employed more than one method of antigenic stimulation. **b** Tissue type analysed; *PBMC* peripheral blood mononuclear cells. **c** Expression profiling method: *HTS* high throughput sequencing. **d** Manipulation of data, *go* gene ontology

Transcriptional insights into the immune response to malaria infection {#Sec6}
----------------------------------------------------------------------

Seven datasets provided insight into the transcriptional changes associated with NAI to malaria (Table [3](#Tab3){ref-type="table"}) \[[@CR24]--[@CR26], [@CR28]--[@CR31]\]. However, given the difficulty in defining or quantifying NAI for an individual, studies varied in their approach, choosing to examine GEPs in settings of varying history of prior exposure to malaria \[[@CR25], [@CR26], [@CR28], [@CR29]\], symptomatology during infection \[[@CR25]\] or severity of disease \[[@CR24], [@CR32]\]. All studies examining NAI included small numbers of subjects and all deployed different experimental designs (Table [3](#Tab3){ref-type="table"}).Table 3Gene expression studies informing understanding of naturally acquired immunity to malaria infectionMeasure of NAIPublicationDesignSampleSpeciesSubjects for comparisonKey findingCommentPrior exposure to malariaTran et al. (2016)Comparison of GEP changes from paired infected and uninfected samplesWhole blood*P. falciparum*Malaria-naïve, symptomatic Dutch CHMI volunteers at diagnosis (n = 5)Malaria experienced Malian children (\> 13 years) and adults infected in the field (n = 8)Graded activation of pathways of downstream proinflammatory cytokines with highest activation in malaria-naive subjects and significantly reduced activation in malaria experienced MaliansOckenhouse et al. (2006)Comparison of GEP changes in infection-controls samples US malaria naïve subjectsPBMC*P. falciparum*US malaria-naïve CHMI volunteers with early, blood-stage infection (n = 22)Malaria-experienced Cameroonian adults presenting with naturally acquired febrile malaria (n = 15)Similar induction of pro-inflammatory cytokines seen between pre-symptomatic and symptomatic individuals regardless of prior malaria exposureRojas-Pena et al. (2015) and Vallejo et al. (2018)Comparison of GEP changes from paired infected and uninfected samplesWhole blood*P. vivax*Columbian malaria-naïve (MN) CHMI volunteers at diagnosis (n = 7)Columbian malaria-exposed (ME) CHMI volunteers at diagnosis (n = 9)Little differentiation seen between MN and ME populations by Rojas-Penas et al. However network co-expression analysis by Vallejo et al. showed the inflammatory response was attenuated in ME volunteers with decreased class II antigen presentation in dendritic cellsNo significant difference between groups for pre-patent period or parasitaemia at diagnosis suggesting there may have been no difference in functional immunity between groupsJagannathan et al. (2014)Comparison of GEP between groupsVδ2^+^ T cells*P. falciparum*Ugandan children with low prior malaria incidence (n = 4)Ugandan children with low prior malaria incidence (n = 4)Comparison of basal gene expression patterns of sorted, un-stimulated Vδ2^+^ T cells identified 48 differentially expressed genes, many with known roles in immunomodulation. For each of these genes, expression was higher among children with high prior exposure to malariaData suggest recurrent malaria infection causes up-regulation of immunoregulatory pathways that dampen the pro-inflammatory immune response to *P. falciparum* infection and help explain immunological tolerance to the parasiteSymptoms at diagnosisTran et al. (2016)Comparison of GEP changes from paired infected and uninfected samplesWhole blood*P. falciparum*Malaria experienced Malian children (\> 13 years) and adults infected in the field and asymptomatic at diagnosis (EA, n = 5)Malaria experienced Malian children (\> 13 years) and adults infected in the field and symptomatic with fever at the time of diagnosis (EF, n = 3)Only 70 differentially expressed genes (DEGs) were identified between these groups despite the apparent clinical differences2 of the 5 individuals in the EA group progressed to febrile malaria within 5 days of initial diagnosis by PCRDisease severityKrupka et al. (2012)Comparison of GEP in same subjects at diagnosis with severe and subsequent mild malariaWhole blood*P. falciparum*Malawian children who, after presenting with severe malaria (all had cerebral malaria), were found to have mild malaria one month later on screening by blood smear (n = 5)Pathway analysis showed relative up regulation of Type I IFN signaling pathway, regulation of inflammation, regulation of leukocyte proliferation and T cell activation in episodes of mild malariaBoldt et al. (2019)Comparison of GEP between groupsWhole blood*P. falciparum*Healthy uninfected Gabonese childrenGabonese children with asymptomatic parasitaemia, mild malaria, malaria with severe anaemia and cerebral anaemia (0.5--6 years)GEP of 22 genes significantly differed among groups. Immunoglobulin production, complement regulation and IFN beta signaling were most conspicuous*PBMC* peripheral blood mononuclear cells, *GEP* gene expression profile, *CHMI* controlled human malaria infection

The findings from a number of studies supported a dampening of the innate pro-inflammatory immune response as a mechanism underpinning NAI \[[@CR24]--[@CR26], [@CR33]\] although this finding was not observed in all studies \[[@CR28], [@CR29], [@CR31]\].

One study by Franklin et al. provided evidence of 'pro-inflammatory priming' of the innate immune system in acute malaria infection \[[@CR34]\]. Comparison of GEP in Brazilian adults presenting with uncomplicated malaria with paired convalescent samples showed an increase in expression in genes involved in TLR signalling pathways supporting a role for TLR hyper responsiveness in the pathology of malaria infection \[[@CR34], [@CR35]\].

Quin et al. sought to use RNA sequencing to elucidate the mechanism driving lower infection rates, lower parasite densities and fewer symptomatic cases of *P. falciparum* in the population of Fulani compared to other sympatric ethnic groups \[[@CR33]\]. Comparison of the GEP of monocytes from infected and uninfected Fulani and Mossi adults showed a marked difference, with a significantly greater number of differentially expressed (DE) genes in infected Fulani compared to infected Mossi participants (1239 versus 3 DE genes respectively). Pathway analysis showed that infected Fulani, but not infected Mossi, individuals demonstrated a marked reduction in expression of inflammasome pathway components, suggesting a blunting of the innate pro-inflammatory immune response post-infection could explain the differences in susceptibility.

Another study sought to examine the genetic basis of gene expression variation in malaria \[[@CR36]\]. Idaghdour et al. compared GEP in children diagnosed with uncomplicated malaria (n = 94) in Benin with age matched controls (n = 64) \[[@CR36]\] and performed a genome wide association test of transcript abundance. Testing for genotype-by-infection interactions demonstrated the existence of genome wide significant interactions and other genes subject to interaction effects beneath genome-wide significance but still likely to have important roles in modulating the course of infection. These interactions affected the complement system, antigen processing and presentation and T cell activation \[[@CR36]\].

In work to identify a transcriptional signature to distinguish acute malaria from other febrile illnesses, Griffiths et al. compared the GEP of twenty-two Kenyan children admitted with febrile illnesses (fifteen of which had malaria infection alone) with six convalescent samples collected 2 weeks post discharge \[[@CR23]\]. Two main GEPs relating to neutrophil and erythroid activity were shown to differentiate acutely ill and convalescent children, with significantly higher expression of genes in the neutrophil-related gene region in subjects with bacterial infections and significantly higher expression of genes related to lymphocyte and T cell activation in subjects with malaria. The authors also identified two gene profiles whose expression intensity correlated with host parasitaemia.

Only two datasets included gene expression changes following *P. vivax* infection \[[@CR28], [@CR30], [@CR37]\]. Rojas-Penas et al. interrogated GEP changes in malaria naïve (MN) and malaria-exposed (ME) Columbian volunteers following infection with *P. vivax* in a CHMI setting \[[@CR28]\]. Significant GEP changes were consistent with time-point rather than prior malaria exposure, with a decline in innate immune signalling and neutrophil number (in contrast to strong up regulation of the same genes reported by Igadour et al. \[[@CR36]\]) and an increase in interferon induction seen at diagnosis. No significant GEP changes were noted at other time points, including those relating to the liver stage of infection. Further analysis of this dataset by Vallejo et al. using network co-expression analysis showed that while *P. vivax* infection induced strong inflammatory responses in all participants, the inflammatory response was attenuated with pathways associated with antigen processing and presentation less enriched in those with prior exposure to *P. vivax*, suggesting a more 'tolerogenic' immune response in these individuals \[[@CR30]\].

In contrast to this work, Rothen et al. found that transcriptional changes post-CHMI via intradermal injection of cryopreserved *P. falciparum* sporozoites were most pronounced on day 5 after inoculation, during the clinically silent liver stage rather than during the blood-stage of infection \[[@CR38]\].

Transcriptomic studies in specific cell types {#Sec7}
---------------------------------------------

Whilst the majority of studies examined the immune response from whole blood or PBMCs, some examined transcriptomic changes in other cell types or tissues \[[@CR26], [@CR33], [@CR39]--[@CR45]\]. For example, the work of Muehlenbachs et al. with placental tissue highlighted a previously unappreciated role for B cells in chronic placental malaria \[[@CR39]\]; whilst Sullivan et al. compared GEPs of classical and 'atypical' memory B cells obtained from Ugandan children showing the latter demonstrated down-regulation of B cell receptor signalling and apoptosis \[[@CR43]\].

Discussion {#Sec8}
==========

GEP is a powerful tool to analyse the immune response to infection. As this review demonstrates, the application of these studies for malaria are wide-ranging, from attempts to dissect the mechanisms of NAI to improving understanding of the interaction between host genotype and infection outcome. However, as a field in its relative infancy, studies are often hypothesis generating with extremely small sample sizes. There is a lack of standardization ranging from methodological (such as sample type, RNA extraction, platform and analysis) to phenotype (including precision in disease context and immune status). This variation means interpreting published data and comparison between studies is challenging. Some of this is unavoidable, however, much could be addressed, for example by implementing standardization in blood sampling, methodological protocols for data generation and analysis with robust significance testing and approaches to confounders, use of ontologies (for example human phenotype and gene ontologies) and expert curation and annotation of data on deposition \[[@CR46]--[@CR49]\].

GEP studies are well placed to examine the mechanisms of NAI and have already helped highlight the role of the innate and early adaptive immune responses \[[@CR24]--[@CR26]\]. However, work has been limited by the lack of an in vitro correlate or universally accepted definition of NAI, meaning identifying the immune status of individuals or quantification of immunity is problematic \[[@CR6], [@CR50]\]. In field studies where the timing of infection and parasite burden and dynamics are unknown, and potentially hugely variable between individuals, only limited information can be reliably extrapolated from any GEP changes seen. Most studies assess gene expression from peripheral blood or its components, which does not provide reliable information regarding the transcriptional changes in key organs such as spleen, liver, and bone marrow. In addition, when subjects are recruited at presentation with disease, no baseline comparator data are available to use as a control. Even if a clear difference in GEP were to be reported between individuals with and without NAI, it would be near impossible to distinguish GEP changes associated with parasitaemia from those mediating immunity.

However, there is much potential for the future use of GEP studies, particularly in CHMI studies \[[@CR51], [@CR52]\] where the parasite burden can be pre-defined and dynamics of infection closely monitored using highly sensitive qPCR. As these studies are increasingly performed in endemic settings \[[@CR53]--[@CR55]\], there will be growing opportunity to use GEP to understand detailed time-course changes in immune response, particularly at the skin, liver and pre-symptomatic blood-stage, which to date have been difficult to study in human subjects infected in the field.

Conclusion {#Sec9}
==========

GEP in malaria is a potentially powerful tool, but to date studies have been hypothesis generating with small sample sizes and widely varying methodology. As CHMI studies are increasingly performed in endemic settings, there will be growing opportunity to use GEP to understand detailed time-course changes in host response and understand in greater detail the mechanisms of NAI.

Supplementary information
=========================
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**Additional file 1: Figure S1.** Flowchart summarizing identification of GEO datasets and publications.

CHMI

:   controlled human malaria infection

GEO

:   gene expression omnibus

GEP

:   gene expression profile

NAI

:   naturally acquired immunity

PBMC

:   peripheral blood mononuclear cells
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